Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

2,843

Participants

Timeline

Start Date

June 27, 2021

Primary Completion Date

February 4, 2022

Study Completion Date

August 2, 2022

Conditions
COVID-19SARS-CoV-2
Interventions
BIOLOGICAL

AZD1222

10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.

BIOLOGICAL

AZD2816

10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.

Trial Locations (35)

1818

Research Site, Johannesburg

2013

Research Site, Johannesburg

2092

Research Site, Johannesburg

7130

Research Site, Somerset West

7500

Research Site, Cape Town

9301

Research Site, Bloemfontein

70200-730

Research Site, Brasília

80810-050

Research Site, Curitiba

59020-035

Research Site, Natal

59025-050

Research Site, Natal

90035-903

Research Site, Porto Alegre

40110-060

Research Site, Salvador

20-362

Research Site, Lublin

32-600

Research Site, Oświęcim

24-100

Research Site, Puławy

22-400

Research Site, Zamość

B15 2TH

Research Site, Birmingham

BH7 7DW

Research Site, Bournemouth

BS105NB

Research Site, Bristol

BS2 8BJ

Research Site, Bristol

EH16 4SA

Research Site, Edinburgh

HA1 3UJ

Research Site, Harrow

HU3 2KZ

Research Site, Hull

E2 0HL

Research Site, London

NW1 2BH

Research Site, London

SE1 9RT

Research Site, London

SE5 9NU

Research Site, London

M8 5RB

Research Site, Manchester

NE1 4LP

Research Site, Newcastle upon Tyne

NG7 2QW

Research Site, Nottingham

OX3 7EJ

Research Site, Oxford

PL6 8DH

Research Site, Plymouth

PO1 3HN

Research Site, Portsmouth

S5 7AU

Research Site, Sheffield

TR1 3LJ

Research Site, Truro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY